Vicore Pharma Holding AB (publ) research snapshot
VCRE AI stock analysis reads Vicore Pharma as a high-risk, high-upside clinical-stage biopharmaceutical company developing first-in-class angiotensin II type 2 receptor agonists (ATRAGs). The lead candidate buloxibutid (C21) is being tested in the global Phase 2b ASPIRE trial for idiopathic pulmonary fibrosis (IPF), with valuation depending almost entirely on whether that trial succeeds. At the July 12, 2026 data cutoff, VCRE traded near $14.15 with a verified market capitalization near $452.84 million. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$14.15
Market cap
$452.84 million
AI score
38 / 100
Rating
Speculative clinical-stage biotech, binary Phase 2b risk
Trend status
Near 52-week lows, awaiting ASPIRE Phase 2b topline data
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Vicore is a clinical-stage biotech with no approved products or recurring revenue. Business quality cannot be assessed until the ASPIRE Phase 2b trial delivers data. | Low |
| Moat | Vicore holds intellectual property around ATRAGs and has Orphan Drug and Fast Track designations from the FDA, but any moat is unproven until clinical validation and regulatory approval are achieved. | Low |
| Management | Management has advanced buloxibutid through Phase 1 and Phase 2a, secured FDA designations, and recently appointed a new CSO, but the team has not yet commercialized a product or generated revenue. | Medium-low |
| Financial trend | Vicore generates negligible revenue (approx. $413K) and burns cash on R&D. Net loss for FY2025 was approximately $51.66 million. Cash runway depends on trial timelines and potential capital raises. | Medium |
| Valuation | At $14.15 with a $452.84M market cap, VCRE trades entirely on option value for buloxibutid success. Standard valuation multiples are not meaningful for a pre-revenue biotech. | Low |
| Technical trend | VCRE has traded in a range from approximately $13.40 to $17.80 over the past 52 weeks. The stock is near the low end of that range, reflecting cautious positioning ahead of ASPIRE data. | Medium-low |
| Risk level | Extreme. Binary Phase 2b readout risk, no approved products, no revenue, cash burn, potential dilution, single-pipeline dependency, and IPF competitive landscape with approved therapies. | High |
| AI confidence | Medium for descriptive facts and financial data; low for forward scenarios and valuation because clinical-stage biotech is inherently binary. | Medium data confidence |
| Investment certainty | Low. Vicore is suitable only for high-risk-tolerant investors who understand binary clinical trial risk and the possibility of total capital loss. | Low |
VCRE AI stock forecast
The VCRE AI stock forecast uses scenario ranges around the $14.15 ADR price and the binary nature of the ASPIRE Phase 2b readout. The framework produces a bearish area near $3 to $5, a base case centered on the current $11 to $17 range, and a bullish scenario in the $28 to $40 range. All scenarios depend on the buloxibutid data, financing, and IPF market dynamics.
$28 to $40
More likely if the ASPIRE Phase 2b trial meets primary endpoints with statistically significant and clinically meaningful results, buloxibutid safety profile is clean, and the company secures partnership or financing to advance to Phase 3.
$11 to $17
More likely if the stock trades range-bound while awaiting ASPIRE data, with price driven by cash position, trial enrollment updates, analyst notes, and general biotech sentiment rather than fundamental news.
$3 to $5
More likely if the ASPIRE trial misses primary endpoints, shows safety concerns, or faces enrollment delays. A failure could significantly impair the stock given Vicores single-pipeline dependency.
VCRE AI technical analysis
VCRE AI technical analysis is limited by low ADR trading volume and the stocks binary biotech nature. As of the July 12, 2026 data cutoff, VCRE traded near $14.15, closer to the bottom of its $13.40 to $17.80 52-week range, with below-average volume reflecting cautious positioning before the ASPIRE Phase 2b readout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $14.15 | Quote snapshots around the July 8 close placed VCRE near $14.15 on the NasdaqCM. |
| Near support | $13.40 | The 52-week low near $13.40 is the immediate support. A break below this level would signal extreme bearish sentiment. |
| Deeper support | $10 area | If $13.40 fails, the next psychological support is the $10 area, near where the stock traded before the AIR Phase 2a data. |
| Near resistance | $15.00 to $15.50 | The 20-day and 50-day moving averages likely sit in this zone, acting as initial resistance on any bounce. |
| 52-week high | $17.80 | The 52-week high near $17.80 represents the upper end of the recent range and a breakout target if positive news emerges. |
| Volume | Average volume near 263K shares | Average daily volume on the ADR is modest at approximately 263,133 shares, making large moves possible on modest news-driven buying or selling. |
| Volatility | High, typical for clinical-stage biotech | Biotech stocks with binary catalysts can move 20% to 50% or more on trial data announcements, regardless of prior technical patterns. |
| Invalidation | Close below $13.40 on above-average volume | A decisive break below the 52-week low on elevated volume would indicate that market expectations for ASPIRE have deteriorated significantly. |
VCRE AI trading strategy
The VCRE AI trading strategy is a risk-management framework for monitoring a binary clinical-stage biotech catalyst. It is not personal advice and should be paired with trial timeline tracking, cash runway monitoring, fresh chart data, position sizing, and the understanding that total capital loss is possible.
Monitor the ASPIRE Phase 2b enrollment completion and topline data timeline. Position size must reflect the binary nature of the readout. Track Vicore press releases, clinicaltrials.gov updates, and IPF conference presentations for timeline visibility.
Define maximum loss before entry. Clinical-stage biotech binary events can result in 60% to 80+% downside on a failed trial. No position should be sized where such a loss is unacceptable.
If VCRE continues to trade in the $13.40 to $17.80 range without catalyst news, the setup is purely technical with wide bid-ask spreads on the ADR. Low-frequency monitoring is appropriate.
Avoid averaging down into a stock whose primary value driver is a binary, unreadable clinical outcome. Range trades in pre-data biotech carry asymmetric downside risk.
After ASPIRE data, reassess based on whether the primary endpoint was met, the magnitude of effect, safety profile, competitive positioning against Ofev and Esbriet, and the path to Phase 3 and regulatory filing.
Do not chase a post-data spike without understanding the data quality and the remaining regulatory and commercial pathway. Positive Phase 2b data does not guarantee Phase 3 or FDA approval success.
Investment research summary
Vicore is developing oral drugs that activate the AT2 receptor to treat fibrotic lung diseases. Patients and doctors would pay for a therapy that slows IPF progression with fewer side effects than current treatments.
Any moat is hypothetical until clinical validation. ATRAG IP, Orphan Drug exclusivity, and Fast Track status provide some protection, but the IPF market already has approved therapies (Ofev, Esbriet) and a competitive pipeline.
The thesis fails if buloxibutid does not meet its Phase 2b endpoint, shows an unfavorable safety profile, requires a larger or longer Phase 3 program than expected, or is outperformed by competing IPF candidates.
The senior leadership team has relevant biotech and pharmaceutical experience, but has not yet taken a product through approval and commercialization. The recent CSO appointment signals R&D focus.
IPF is a serious unmet medical need with a growing patient population, but the competitive landscape includes established therapies and multiple pipeline candidates targeting different mechanisms.
At roughly $452.84M market cap with zero revenue, VCRE is priced on option value. Margin of safety does not exist in any traditional sense. Investment depends entirely on the probability-weighted value of buloxibutid success.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VCRE ADR price | $14.15 | Yahoo Finance quote snapshot | July 12, 2026 |
| Market capitalization | $452.84 million, verified as approx. $14.15 x 32.0M ADR shares | financial_rigor.py market cap verification | July 12, 2026 |
| FY2025 revenue | Approximately $413,000 | TradingView fundamentals snapshot | July 12, 2026 |
| FY2025 net income | Approximately -$51.66 million (net loss) | TradingView fundamentals snapshot | July 12, 2026 |
| EPS (TTM) | -$0.18 to -$0.20 | Yahoo Finance statistics snapshot | July 12, 2026 |
| Enterprise value | Approximately $344 million | Yahoo Finance statistics snapshot | July 12, 2026 |
| 52-week range | $13.40 to $17.80 | Yahoo Finance range snapshot | July 12, 2026 |
| Average volume | Approximately 263,133 shares | Yahoo Finance statistics snapshot | July 12, 2026 |
| Lead program | Buloxibutid (C21) ATRAG in Phase 2b ASPIRE trial (NCT06588686) for IPF | Vicore Pharma corporate website | July 12, 2026 |
| Employees | Approximately 40 full-time | Yahoo Finance profile snapshot | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell VCRE stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotech investing carries the risk of total capital loss. Always verify current filings, trial data, prices, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
